Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ceftezole sodium is a first-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and some Gram-negative bacteria. It functions by inhibiting bacterial cell wall synthesis through the binding and inactivation of penicillin-binding proteins (PBPs), which are essential for the cross-linking of peptidoglycan chains. Developed and manufactured by companies such as Sichuan Proud Era Pharmaceutical, it is typically administered via injection (intravenous or intramuscular) for the treatment of various infections, including respiratory, urinary tract, and skin infections. It is approved for clinical use in several countries, particularly in Asia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftezole sodium.